NEW YORK (GenomeWeb) – Predicine said today that it has entered a new global strategic partnership with Suzhou, China-based Kintor Pharmaceuticals, aimed at improving the firm's biomarker-driven clinical trials and developing companion diagnostics for Food and Drug Administration approvals in the US and China.
The effort will use Predicine’s combined DNA and RNA liquid biopsy platform, which it calls "ctRNA and ctDNA single-molecule digital reading," or GeneRADAR for short.
Kintor's oncology pipeline is focused on prostate cancer, breast cancer, and liver cancer. Predicine, which has operations in Hayward, California, and Shanghai, has already collaborated with the company in clinical trials for Kintor's investigational drug proxalutamide for the treatment of prostate cancer and triple negative breast cancer.
Financial terms of the new agreement were not disclosed.